Cargando…

Multi-marker risk-based screening for prostate cancer

OBJECTIVE: To determine prostate cancer screening performance using prostate specific antigen (PSA) along with other markers, expressing markers in age-specific multiples of the median (MoM), and age. METHODS: A prospective nested case-control study used stored serum from 571 men who died of, or wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wald, Nicholas J, Bestwick, Jonathan P, Morris, Joan K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087319/ https://www.ncbi.nlm.nih.gov/pubmed/35255236 http://dx.doi.org/10.1177/09691413221076415

Ejemplares similares

Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's Syndrome
por: Wald, Nicholas J., et al.
Publicado: (2013)

Prenatal maternal plasma DNA screening for cystic fibrosis: A computer modelling study of screening performance
por: Old, Robert W., et al.
Publicado: (2017)

Prevention of Neural Tube Defects: A Cross-Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women
por: Bestwick, Jonathan P., et al.
Publicado: (2014)

Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13
por: Bestwick, Jonathan Paul, et al.
Publicado: (2019)

Improvements in antenatal screening for Down's syndrome
por: Wald, N J, et al.
Publicado: (2013)

Distribution of nuchal translucency in antenatal screening for Down's syndrome
por: Bestwick, J P, et al.
Publicado: (2010)

Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests
por: Wald, Nicholas J., et al.
Publicado: (2012)

Evaluation of a proposed mixture model to specify the distributions of nuchal translucency measurements in antenatal screening for Down's syndrome
por: Bestwick, J P, et al.
Publicado: (2010)

Randomized Crossover Trial of Phosphate-binding Medication on Serum Phosphate Levels in Patients With Aortic Stenosis
por: Wald, David S., et al.
Publicado: (2019)

Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age
por: Wald, Nicholas J., et al.
Publicado: (2011)

Randomised Trial of Text Messaging on Adherence to Cardiovascular Preventive Treatment (INTERACT Trial)
por: Wald, David S., et al.
Publicado: (2014)

Occupational Exposure to Hydrazine and Subsequent Risk of Lung Cancer: 50-Year Follow-Up
por: Morris, Joan K., et al.
Publicado: (2015)

Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
por: Wald, N J, et al.
Publicado: (2000)

Scanning electron microscopy for blood micro-crystals in aortic stenosis patients
por: Wald, David S., et al.
Publicado: (2018)

Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog
por: Hingorani, Aroon D, et al.
Publicado: (2023)

Evaluation of stability of directly standardized rates for sparse data using simulation methods
por: Morris, Joan K., et al.
Publicado: (2018)

The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer.
por: Law, M. R., et al.
Publicado: (1997)

Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis
por: Wald, David S., et al.
Publicado: (2011)

Randomized Polypill Crossover Trial in People Aged 50 and Over
por: Wald, David S., et al.
Publicado: (2012)

Integration of child–parent screening and cascade testing for familial hypercholesterolaemia
por: Wald, David S, et al.
Publicado: (2018)

Starting the polypill: the use of a single age cut-off in males and females
por: Wald, Nicholas J, et al.
Publicado: (2016)

Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example
por: Wald, Nicholas J., et al.
Publicado: (2014)

Erratum to: Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example
por: Wald, Nicholas J., et al.
Publicado: (2015)

Urinary markers aiding in the detection and risk stratification of prostate cancer
por: Raja, Nicholas, et al.
Publicado: (2018)

Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer
por: Callender, Thomas, et al.
Publicado: (2021)

Predictors of participation in risk-based prostate cancer screening
por: Koitsalu, Marie, et al.
Publicado: (2018)

Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate
por: Wald, Nicholas J., et al.
Publicado: (2018)

A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Falk, Roni T., et al.
Publicado: (2016)

Population-based Prostate Cancer Screening in Kazakhstan
por: ISHKININ, Yevgeniy, et al.
Publicado: (2017)

Inflammatory Genetic Markers of Prostate Cancer Risk
por: Tindall, Elizabeth A., et al.
Publicado: (2010)

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles
por: Cybulski, C, et al.
Publicado: (2013)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging
por: Osman, Sarah O. S., et al.
Publicado: (2019)

Are screening practice ethics committees needed?
por: Wald, Nicholas
Publicado: (2021)

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen
por: Michael, Zoe D., et al.
Publicado: (2023)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Discussing Uncertainty and Risk in Primary Care: Recommendations of a Multi-Disciplinary Panel Regarding Communication Around Prostate Cancer Screening
por: Wilkes, Michael, et al.
Publicado: (2013)

Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators
por: Liu, Xiaomin, et al.
Publicado: (2023)

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
por: Pashayan, Nora, et al.
Publicado: (2015)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9nd44sk2ql27csni2et5hi1bhr